JP2023021979A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023021979A5 JP2023021979A5 JP2022171607A JP2022171607A JP2023021979A5 JP 2023021979 A5 JP2023021979 A5 JP 2023021979A5 JP 2022171607 A JP2022171607 A JP 2022171607A JP 2022171607 A JP2022171607 A JP 2022171607A JP 2023021979 A5 JP2023021979 A5 JP 2023021979A5
- Authority
- JP
- Japan
- Prior art keywords
- application
- xml
- entirety
- hereby incorporated
- sequence listing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662289671P | 2016-02-01 | 2016-02-01 | |
| US62/289,671 | 2016-02-01 | ||
| JP2018559673A JP2019511562A (ja) | 2016-02-01 | 2017-02-01 | Ｒｎａ媒介疾患を処置する化合物および方法 |
| JP2021087002A JP7167248B2 (ja) | 2016-02-01 | 2021-05-24 | Ｒｎａ媒介疾患を処置する化合物および方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021087002A Division JP7167248B2 (ja) | 2016-02-01 | 2021-05-24 | Ｒｎａ媒介疾患を処置する化合物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023021979A JP2023021979A (ja) | 2023-02-14 |
| JP2023021979A5 true JP2023021979A5 (enExample) | 2023-04-11 |
Family
ID=59499945
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559673A Pending JP2019511562A (ja) | 2016-02-01 | 2017-02-01 | Ｒｎａ媒介疾患を処置する化合物および方法 |
| JP2021087002A Active JP7167248B2 (ja) | 2016-02-01 | 2021-05-24 | Ｒｎａ媒介疾患を処置する化合物および方法 |
| JP2022171607A Pending JP2023021979A (ja) | 2016-02-01 | 2022-10-26 | Ｒｎａ媒介疾患を処置する化合物および方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559673A Pending JP2019511562A (ja) | 2016-02-01 | 2017-02-01 | Ｒｎａ媒介疾患を処置する化合物および方法 |
| JP2021087002A Active JP7167248B2 (ja) | 2016-02-01 | 2021-05-24 | Ｒｎａ媒介疾患を処置する化合物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200115372A1 (enExample) |
| EP (1) | EP3411080A4 (enExample) |
| JP (3) | JP2019511562A (enExample) |
| CN (2) | CN115721729A (enExample) |
| AU (1) | AU2017215201B2 (enExample) |
| CA (1) | CA3012700A1 (enExample) |
| IL (2) | IL260859B (enExample) |
| MX (1) | MX2018009325A (enExample) |
| RU (1) | RU2018127537A (enExample) |
| SG (1) | SG11201806544XA (enExample) |
| WO (1) | WO2017136450A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201811643TA (en) * | 2016-07-01 | 2019-01-30 | Arrakis Therapeutics Inc | Compounds and methods for modulating rna function |
| WO2018151810A1 (en) | 2017-02-17 | 2018-08-23 | The Scripps Research Institute | Defining rna-small molecule affinity landscapes enables design of a small molecular inhibitor of an oncogenic non-coding rna |
| MX2020001425A (es) | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| MX2020003695A (es) | 2017-11-30 | 2020-08-03 | Arrakis Therapeutics Inc | Fotosondas de union a acido nucleico y usos de las mismas. |
| WO2019236644A1 (en) * | 2018-06-05 | 2019-12-12 | Arrakis Therapeutics, Inc. | Encoded libraries and methods of use for screening nucleic acid targets |
| US12661409B2 (en) | 2018-10-10 | 2026-06-23 | University Of Florida Research Foundation, Incorporated | Target validation and profiling of the RNA targets of small molecules |
| CN109928933B (zh) * | 2019-01-10 | 2021-02-26 | 安徽昊帆生物有限公司 | 2-氯-5-醛基嘧啶及其制备方法 |
| WO2020163248A1 (en) | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| WO2020163541A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| KR102913697B1 (ko) | 2019-02-05 | 2026-01-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| KR102925385B1 (ko) | 2019-02-06 | 2026-02-11 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| JP7603594B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| US20220073910A1 (en) * | 2019-02-12 | 2022-03-10 | The Scripps Research Institute | A Cross-Linking Approach to Map Small Molecule-RNA Binding Sites in Cells |
| WO2020264572A1 (en) * | 2019-06-27 | 2020-12-30 | The Scripps Research Institute | Fragment-based screening to identify small molecules that selectively bind rna |
| WO2021087084A1 (en) | 2019-10-29 | 2021-05-06 | The Scripps Research Institute | COMPOUNDS AND MODULES FOR INHIBITION OF PRE-miR-21 AND THEIR USE IN TREATMENT OF CERTAIN CANCERS |
| TW202131920A (zh) * | 2019-11-01 | 2021-09-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
| GB2591088B (en) * | 2020-01-08 | 2024-07-03 | Adv Med Solutions Ltd | Antimicrobial fibres |
| JP2024542018A (ja) * | 2021-10-28 | 2024-11-13 | アラーキス セラピューティクス， インコーポレイテッド | Ｒｎａ分解剤およびその使用 |
| CN114373522B (zh) * | 2022-01-13 | 2024-09-27 | 腾讯科技（深圳）有限公司 | 分子生成模型的训练方法、装置、设备及存储介质 |
| EP4463188A4 (en) * | 2022-01-14 | 2025-10-22 | Univ Leland Stanford Junior | CHEMICALLY REVERSIBLE 2´-OH ACYLATION PROTECTS RNA FROM HYDROLYTIC AND ENZYMATIC DEGRADATION |
| JP2025539353A (ja) * | 2022-11-23 | 2025-12-05 | アラーキス セラピューティクス， インコーポレイテッド | Ｒｎａ分解剤およびその使用 |
| CN115850907B (zh) * | 2022-12-29 | 2024-12-17 | 福建泓光半导体材料有限公司 | 一种酚醛树脂组合物及其制备方法和应用以及固化浮雕图案的制备方法 |
| CN119320798A (zh) * | 2023-07-17 | 2025-01-17 | 中国科学院上海营养与健康研究所 | 一种可用于筛选针对rna重复序列药物的报告系统 |
| WO2025024573A1 (en) * | 2023-07-24 | 2025-01-30 | Arrakis Therapeutics, Inc. | Ccr4-not binding rna degraders |
| WO2025137537A1 (en) * | 2023-12-22 | 2025-06-26 | Arrakis Therapeutics, Inc. | Compositions and methods for treating myc-mediated diseases |
| WO2025184391A1 (en) * | 2024-02-27 | 2025-09-04 | Arrakis Therapeutics, Inc. | Covalent inhibitors and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6354363A (ja) * | 1986-08-26 | 1988-03-08 | Ss Pharmaceut Co Ltd | キノリン誘導体 |
| US5514786A (en) * | 1990-01-11 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Compositions for inhibiting RNA activity |
| EP2048142A3 (en) | 2001-04-26 | 2009-04-22 | Eisai R&D Management Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| CA2678967C (en) * | 2007-02-23 | 2013-10-01 | The Research Foundation Of State University Of New York | Rna targeting compounds and methods for making and using same |
| CN103819403B (zh) * | 2008-12-31 | 2017-01-04 | 阿德利克斯公司 | 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法 |
| BR112015000236A2 (pt) * | 2012-07-10 | 2017-06-27 | Baseclick Gmbh | moléculas de ácidos nucleicos modificadas por anandamida |
| HK1210460A1 (en) * | 2012-07-10 | 2016-04-22 | Georgia State University Research Foundation, Inc. | Anthraquinone analogs and methods of making and using thereof |
| US8729263B2 (en) * | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| WO2016069922A1 (en) * | 2014-10-29 | 2016-05-06 | Biotium, Inc. | Nucleic acid modifying agents and uses thereof |
-
2017
- 2017-02-01 CN CN202211442068.6A patent/CN115721729A/zh active Pending
- 2017-02-01 CN CN201780018534.9A patent/CN108778345B/zh active Active
- 2017-02-01 US US16/074,232 patent/US20200115372A1/en not_active Abandoned
- 2017-02-01 EP EP17748078.7A patent/EP3411080A4/en not_active Withdrawn
- 2017-02-01 JP JP2018559673A patent/JP2019511562A/ja active Pending
- 2017-02-01 WO PCT/US2017/016065 patent/WO2017136450A2/en not_active Ceased
- 2017-02-01 SG SG11201806544XA patent/SG11201806544XA/en unknown
- 2017-02-01 RU RU2018127537A patent/RU2018127537A/ru unknown
- 2017-02-01 MX MX2018009325A patent/MX2018009325A/es unknown
- 2017-02-01 CA CA3012700A patent/CA3012700A1/en active Pending
- 2017-02-01 AU AU2017215201A patent/AU2017215201B2/en active Active
-
2018
- 2018-07-30 IL IL260859A patent/IL260859B/en active IP Right Grant
-
2021
- 2021-05-24 JP JP2021087002A patent/JP7167248B2/ja active Active
- 2021-06-08 IL IL283799A patent/IL283799B/en unknown
- 2021-12-17 US US17/644,986 patent/US20220281860A1/en not_active Abandoned
-
2022
- 2022-10-26 JP JP2022171607A patent/JP2023021979A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019502892A5 (enExample) | ||
| JP2021524958A5 (enExample) | ||
| CN110352605A (zh) | 一种鉴权算法程序的添加方法、相关设备及系统 | |
| BRPI0515554A (pt) | anticorpos anti-ox40l | |
| WO2007038239A3 (en) | Processing software images and generating difference files | |
| JP2019514354A5 (enExample) | ||
| JP2022518511A5 (enExample) | ||
| JP2018520447A5 (enExample) | ||
| CN110214154A (zh) | 抗cd47抗体及其用途 | |
| JP2022521336A5 (enExample) | ||
| CN111655682A (zh) | 一种高活性sting蛋白激动剂化合物 | |
| JP2023502438A5 (enExample) | ||
| JP2015512691A5 (enExample) | ||
| WO2004106380A3 (en) | Human-anti-human cd3 binding molecules | |
| JP2012504317A5 (enExample) | ||
| JP2014520155A5 (enExample) | ||
| JP2020530380A5 (enExample) | ||
| JP2014507581A5 (enExample) | ||
| JP2014533241A5 (enExample) | ||
| JP2014508098A5 (enExample) | ||
| JP2021500874A5 (enExample) | ||
| CN111836665A (zh) | 放射治疗系统及其验证装置、验证方法 | |
| JP2021502362A5 (enExample) | ||
| JP2019527311A5 (enExample) | ||
| JP2020505322A5 (enExample) |